CA1168154A - Stabilised ophthalmic formulation - Google Patents
Stabilised ophthalmic formulationInfo
- Publication number
- CA1168154A CA1168154A CA000373477A CA373477A CA1168154A CA 1168154 A CA1168154 A CA 1168154A CA 000373477 A CA000373477 A CA 000373477A CA 373477 A CA373477 A CA 373477A CA 1168154 A CA1168154 A CA 1168154A
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- isotonic
- trimethoprim
- polymyxin
- preservative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 238000009472 formulation Methods 0.000 title claims abstract description 50
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000003755 preservative agent Substances 0.000 claims abstract description 27
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims abstract description 27
- 239000007951 isotonicity adjuster Substances 0.000 claims abstract description 24
- 230000002335 preservative effect Effects 0.000 claims abstract description 24
- 229960001082 trimethoprim Drugs 0.000 claims abstract description 16
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims abstract description 15
- 108010040201 Polymyxins Proteins 0.000 claims abstract description 13
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229910052753 mercury Inorganic materials 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000008121 dextrose Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229940068917 polyethylene glycols Drugs 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000001117 sulphuric acid Substances 0.000 claims description 4
- 235000011149 sulphuric acid Nutrition 0.000 claims description 4
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 claims description 3
- 239000002997 ophthalmic solution Substances 0.000 claims description 2
- 239000008215 water for injection Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims 4
- 239000012467 final product Substances 0.000 claims 1
- 229940054534 ophthalmic solution Drugs 0.000 claims 1
- 229920006324 polyoxymethylene Polymers 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 abstract description 5
- 229960004906 thiomersal Drugs 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- -1 carbohydrate compounds Chemical class 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- JWHHANVGNNWIRI-UHFFFAOYSA-N methanol phosphoric acid hydrate Chemical compound O.OC.OP(O)(O)=O JWHHANVGNNWIRI-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- UILMMYFRNCCPLK-UHFFFAOYSA-N sulfuric acid;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound OS(O)(=O)=O.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 UILMMYFRNCCPLK-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8009589 | 1980-03-21 | ||
| GB8009589 | 1980-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1168154A true CA1168154A (en) | 1984-05-29 |
Family
ID=10512277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000373477A Expired CA1168154A (en) | 1980-03-21 | 1981-03-20 | Stabilised ophthalmic formulation |
Country Status (30)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62277323A (ja) * | 1986-02-19 | 1987-12-02 | Sankyo Co Ltd | フマル酸ケトチフエン含有点眼液の製法 |
| IL80298A (en) * | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
| FR2622112A1 (fr) * | 1987-10-27 | 1989-04-28 | Medipro | Medicament comprenant l'association de polymyxine b, de neomycine et d'amphotericine b administre par vaporisation |
| ES2012532A6 (es) * | 1988-07-15 | 1990-04-01 | Cusi Lab | Un procedimiento para la preparacion de una solucion acuosa de b-metil-4-(2' -tienilcarbonil)fenilacetato de lisina para aplicacion topica oftalmica. |
| JPH05503527A (ja) * | 1990-02-22 | 1993-06-10 | マクノート・ピーティーワイ・リミテッド | 人工涙液 |
| DE4229494A1 (de) * | 1992-09-04 | 1994-03-10 | Basotherm Gmbh | Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks |
| ES2079994B1 (es) * | 1992-10-07 | 1996-08-01 | Cusi Lab | Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica. |
| WO2005049061A2 (en) | 2003-11-20 | 2005-06-02 | Novo Nordisk A/S | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
| CA2702082A1 (en) * | 2007-10-08 | 2009-04-16 | Fovea Pharmaceuticals Sa | Aqueous ophthalmic formulations |
| CN111050750B (zh) | 2017-08-24 | 2024-09-24 | 诺和诺德股份有限公司 | Glp-1组合物及其用途 |
| WO2021144476A1 (en) | 2020-02-18 | 2021-07-22 | Novo Nordisk A/S | Pharmaceutical formulations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2703777A (en) * | 1950-05-02 | 1955-03-08 | Iso Sol Company Inc | Ophthalmological preparations and vehicles and method of making the same |
| GB1340517A (en) * | 1969-12-01 | 1973-12-12 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US3898330A (en) * | 1973-08-01 | 1975-08-05 | Squibb & Sons Inc | Corticosteroid phosphate salts/neomycin sulfate ophthalmic |
| NL7416636A (nl) * | 1973-12-27 | 1975-07-01 | Wellcome Found | Farmaceutisch preparaat. |
-
1981
- 1981-03-20 IT IT8148073A patent/IT8148073A0/it unknown
- 1981-03-20 KR KR1019810000921A patent/KR830004856A/ko not_active Ceased
- 1981-03-20 GB GB8108806A patent/GB2072015B/en not_active Expired
- 1981-03-20 DD DD81228491A patent/DD157535A5/de not_active IP Right Cessation
- 1981-03-20 JP JP4662981A patent/JPS56150012A/ja active Granted
- 1981-03-20 CA CA000373477A patent/CA1168154A/en not_active Expired
- 1981-03-20 PT PT72703A patent/PT72703B/pt unknown
- 1981-03-20 AU AU68567/81A patent/AU542560B2/en not_active Expired
- 1981-03-20 CS CS812056A patent/CS261206B2/cs unknown
- 1981-03-20 DE DE8181102132T patent/DE3167270D1/de not_active Expired
- 1981-03-20 NO NO810961A patent/NO155377C/no not_active IP Right Cessation
- 1981-03-20 IE IE617/81A patent/IE51035B1/en not_active IP Right Cessation
- 1981-03-20 EP EP81102132A patent/EP0037043B1/en not_active Expired
- 1981-03-20 CY CY136181A patent/CY1361A/xx unknown
- 1981-03-20 ZW ZW64/81A patent/ZW6481A1/xx unknown
- 1981-03-20 PH PH25391A patent/PH17800A/en unknown
- 1981-03-20 HU HU81723A patent/HU185630B/hu unknown
- 1981-03-20 IL IL62447A patent/IL62447A/xx not_active IP Right Cessation
- 1981-03-20 FI FI810870A patent/FI75991C/fi not_active IP Right Cessation
- 1981-03-20 MC MC811508A patent/MC1379A1/xx unknown
- 1981-03-20 DK DK127181A patent/DK159414C/da not_active IP Right Cessation
- 1981-03-20 NZ NZ196571A patent/NZ196571A/xx unknown
- 1981-03-20 ZA ZA00811896A patent/ZA811896B/xx unknown
- 1981-03-20 PL PL1981230236A patent/PL138377B1/pl unknown
- 1981-03-20 GR GR64460A patent/GR73038B/el unknown
- 1981-03-21 EG EG155/81A patent/EG15051A/xx active
- 1981-03-21 IN IN306/CAL/81A patent/IN153498B/en unknown
-
1987
- 1987-02-26 SG SG207/87A patent/SG20787G/en unknown
- 1987-07-09 HK HK527/87A patent/HK52787A/en not_active IP Right Cessation
- 1987-12-30 MY MY517/87A patent/MY8700517A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4829083A (en) | Stabilization of mercury-containing preservatives in ophthalmic medicaments | |
| CA2606370C (en) | Self-preserved aqueous pharmaceutical compositions | |
| EP2420223B1 (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
| EP2066300B1 (en) | Self-preserved aqueous pharmaceutical compositions | |
| CA1168154A (en) | Stabilised ophthalmic formulation | |
| PT95937A (pt) | Sistema de desinfeccao para lentes de contacto utilizando uma n-alquil-2-pirrolidona | |
| US3070499A (en) | Parenteral aqueous solutions of fat soluble vitamins | |
| ITMI20011389A1 (it) | Formulazioni farmaceutiche acquose di cromoglicato sodico | |
| WO2008036855A2 (en) | Self-preserved aqueous pharmaceutical compositions | |
| US4406888A (en) | Aqueous micellar solutions of levonantradol and N-methyllevonantradol and lyophilic forms thereof for reconstitution | |
| JPH10236951A (ja) | プラノプロフェン配合点眼剤 | |
| EP2419081B1 (en) | Aqueous ophthalmic compositions containing anionic therapeutic agents | |
| EP0293503B1 (en) | Urea stabilized with a lactone in various pharmaceutical and cosmetic preparations | |
| Arrigoni et al. | Ophthalmic Zinc Sulfate Solutions: Buffered, Isotonic and Preserved | |
| Bailey et al. | The biological properties of chlorindanol, a new antiseptic agent | |
| LEOPOLD et al. | SPECIFIC TREATMENT OF OCULAR BURNS DUE TO LEWISITE (β-CHLOROVINYLDICHLOROARSINE) | |
| HK1126667B (en) | Self preserved aqueous pharmaceutical compositions | |
| HK1126419B (en) | Self-preserved aqueous pharmaceutical compositions | |
| HK1165327B (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
| HK1155087A (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
| HK1145631B (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |